EBMT 2023 | The role of tisa-cel in the context of allogeneic transplantation in pediatric ALL
Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, discusses the role of tisagenlecleucel (tisa-cel) in pediatric acute lymphoblastic leukemia (ALL), explaining that it can allow patients to achieve a deep remission before allogeneic transplantation, and in certain cases, to omit transplantation. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Medac: Honoraria; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Riemser: Consultancy, Speakers Bureau; Jazz: Other, Research Funding; Neovii: Research Funding.
